Adhesion Barrier Final Guidance Removes Surrogate Endpoint Distinction
This article was originally published in The Gray Sheet
Executive Summary
FDA's final guidance for resorbable adhesion barrier devices used in abdominal and/or pelvic surgery eliminates the definition of adhesion reduction as a surrogate endpoint
You may also be interested in...
Lifecore Intergel Approvable Despite FDA Objections, MDDR Panel Says
Lifecore Biomedical's Gynecare Intergel adhesion prevention solution appears closer to FDA approval following a determination by the agency's Medical Devices Dispute Resolution Panel (MDDRP) that the firm demonstrated a statistically significant treatment effect.
Draft Adhesion Barrier Guidance Overly Burdensome - Industry Task Force
FDA's proposal that clinical studies of resorbable adhesion barrier devices have endpoints other than adhesion reduction is overly burdensome to manufacturers, according to an industry task force.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.